420 with CNW — Research Firm Plans to Study Use of Cannabis as Analgesic

CBD Science Group PLC plans to conduct large-scale trials to evaluate the use of cannabis in managing pain in cancer patients where conventional pain relief isn’t adequate. This will provide an alternative to opioids, which sometimes induce unwanted side effects or interfere with ongoing cancer treatments. Scientists at CBD plan to investigate the use of marijuana-based analgesics, with chief commercial officer Graeme McFarlane stating that the trials will measure the effectiveness and safety of these analgesics in addition to other variables.

McFarlane explained that the company would use various tools including clinician reporting and  self-reporting in patients in its evaluations. This is in addition to exploring the health economics of these medicines and evaluating the actual value of these natural medicines.

The company is planning to begin its research in second quarter 2022 after securing a strong supply chain that can meet its trial requirements. The company may have sufficient evidence to present to the regulatory bodies in the United Kingdom by Q2 2023.

McFarlane also stated that before CBD Science Group expanded to other centers in Europe and the United Kingdom, it would begin trials with 100 to 200 patients. He added that this was what was required for an effective strategy.

In addition to this, he explained that the company would not be conducting randomized controlled trials because the planned studies weren’t designed to use larger datasets, in addition to other factors. He noted that a drug performing well in clinical trials didn’t directly translate to it performing well in the real world.

The company expects to release outcome publications during its study period, with company officials noting that this approach will continue improving access for the many individuals suffering from various indications, in addition to offering a tool to educate clinicians.

At the moment, the company is crowd funding to finance early trials, with its objective being to raise £2 million ($2.74 million). In the long term, the CBD Science Group plans to approach the stock market to source for the capital it needs to develop and expand its business.

The company’s team is made up of the lead for cancer at the National Institute for Health Research Professor Sam Ahmedzai and former NHS England deputy medical director Professor Mike Bewick. The team is also comprised of renowned experts in anaesthetics, pharmacology and palliative care. CBD Science Group CEO Dr. Michael Raymont notes that the company’s strategy is unique and has been developed by experts who understand the regulatory framework and want the best for patients.

If this study yields positive outcomes regarding the analgesic attributes of marijuana, the entire cannabis sector including companies such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) will be vindicated in their conviction that the medicinal potential of cannabis is yet to be fully understood.

NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Archives

Select A Month
  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • September 2016
  • August 2016
  • July 2016
  • Official NewsWire Relationships

    Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition Cannexpo Marigold PR MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo Tether BudTender Tether BudTender Appreciation Week

    CannabisNewsWire Currently Accepts

    Bitcoin

    Bitcoin

    Bitcoin Cash

    Bitcoin Cash

    Doge Coin

    Dogecoin

    Ethereum

    Ethereum

    Litecoin

    Litecoin

    USD Coin

    USD Coin

    Contact us: 512.354.7000